Alkermes Q3 2026 slides: revenue jumps 22% as profits decline

Alkermes reported Q3 2026 revenue of $480.1 million, up 21.8% year over year, while GAAP net income fell 80.3% to $16.3 million and diluted EPS declined to $0.09; Adjusted EBITDA was nearly flat at $120.1 million. The company attributed the profitability pressure primarily to Avadel acquisition costs and acquired-intangible amortization, and reaffirmed full-year revenue guidance of $1.73 billion–$1.84 billion and Adjusted EBITDA of $370 million–$410 million. Shares traded down 5.32% premarket to $42.50, as investors weighed acquisition-related costs and pipeline execution risks against product growth and the revenue beat.

Analysis

The key issue is not the GAAP/non-GAAP gap itself, but whether the adjustments are genuinely temporary. If acquisition charges roll off while R&D rises, the expected 2027 margin benefit may be smaller than the headline cost-reversal implies. Stable adjusted EBITDA alongside higher revenue also makes incremental economics worth testing against cash flow, not just management’s adjusted measure.

Commercial quality is mixed: LUMRYZ adds scale, but patient count and sales do not establish durable persistence, net pricing, or a repeatable acquisition contribution. Verify access, discontinuation, and gross-to-net trends. LYBALVI’s prescription growth paired with rising rebates is a warning that volume may not translate to revenue; continued access concessions could pressure economics and invite competitors to defend share through pricing. VIVITROL’s favorable gross-to-net contribution also creates potential reversal risk, so reported growth may overstate the underlying run rate.

Near term (days to weeks), the negative premarket reaction argues against buying the revenue beat outright. Over 1–3 months, focus on cash conversion, product-level net sales, and any 2027 expense or guidance reset. Over 6–18 months, orexin readouts can create meaningful upside, but they are binary and should not be capitalized as established growth. The contrarian upside is that the market may over-penalize acquisition accounting while underweighting pipeline optionality; that case requires proof that core product economics hold up.

Key Decisions for Investors

• Maintain a neutral-to-underweight stance on ALKS rather than chase the top-line beat. For an existing position, consider a partial hedge; add only after the next update confirms cash conversion and underlying product growth, not merely adjusted EBITDA.
• Treat LYBALVI’s rising gross-to-net deductions and VIVITROL’s favorable gross-to-net benefit as near-term monitoring items. Reassess if LYBALVI net sales continue to lag prescription growth or VIVITROL reverses its gross-to-net support; either would weaken the quality-of-growth thesis.
• Keep orexin pipeline value as optionality, not the base-case earnings driver. Revisit exposure around disclosed 2027 trial readouts, with trial outcomes and timelines as explicit catalysts and failure or delay as thesis falsifiers.
• The underweight thesis is falsified by sustained improvement in operating cash generation, stable or improving net pricing across the commercial portfolio, and evidence that acquisition-related costs decline without a larger-than-expected R&D burden.